[go: up one dir, main page]

WO2004007720A3 - Treatment of proliferative disorders - Google Patents

Treatment of proliferative disorders Download PDF

Info

Publication number
WO2004007720A3
WO2004007720A3 PCT/GB2003/002993 GB0302993W WO2004007720A3 WO 2004007720 A3 WO2004007720 A3 WO 2004007720A3 GB 0302993 W GB0302993 W GB 0302993W WO 2004007720 A3 WO2004007720 A3 WO 2004007720A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
proliferative disorders
medicament
cancer
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/002993
Other languages
French (fr)
Other versions
WO2004007720A2 (en
Inventor
David Hugh Beach
Hiroshi Kondoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College London filed Critical University College London
Priority to AU2003254447A priority Critical patent/AU2003254447A1/en
Publication of WO2004007720A2 publication Critical patent/WO2004007720A2/en
Publication of WO2004007720A3 publication Critical patent/WO2004007720A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of an inhibitor of an enzyme of the glycolytic pathway in the manufacture of a medicament for use in the treatment of a cancer or other proliferative disorder.
PCT/GB2003/002993 2002-07-11 2003-07-11 Treatment of proliferative disorders Ceased WO2004007720A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003254447A AU2003254447A1 (en) 2002-07-11 2003-07-11 Treatment of proliferative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0216097.6 2002-07-11
GB0216097A GB0216097D0 (en) 2002-07-11 2002-07-11 Treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
WO2004007720A2 WO2004007720A2 (en) 2004-01-22
WO2004007720A3 true WO2004007720A3 (en) 2004-04-22

Family

ID=9940259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/002993 Ceased WO2004007720A2 (en) 2002-07-11 2003-07-11 Treatment of proliferative disorders

Country Status (3)

Country Link
AU (1) AU2003254447A1 (en)
GB (1) GB0216097D0 (en)
WO (1) WO2004007720A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595957A1 (en) * 2004-05-12 2005-11-16 Erich Eigenbrodt Phosphoglycerate mutases and enzyme products
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255046B1 (en) * 1997-10-31 2001-07-03 The Picower Institute For Medical Research Inducible phosphofructokinase and the warburg effect
WO2001068667A1 (en) * 2000-03-14 2001-09-20 The Johns Hopkins University School Of Medicine Arrest of proliferation of highly glycolytic tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255046B1 (en) * 1997-10-31 2001-07-03 The Picower Institute For Medical Research Inducible phosphofructokinase and the warburg effect
WO2001068667A1 (en) * 2000-03-14 2001-09-20 The Johns Hopkins University School Of Medicine Arrest of proliferation of highly glycolytic tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEMIR G ET AL: "USE OF RNA INTERFERENCE (RNAI) TO DISRUPT C-KIT GENE EXPRESSION IN MALIGNANT HUMAN HEMATOPOIETIC AND NEUROEPITHELIAL CELLS", BLOOD, vol. 96, no. 11, PART 2, 16 November 2000 (2000-11-16), pages 378B, XP009004894, ISSN: 0006-4971 *
LIU H ET AL: "Hypersensitization of tumor cells to glycolytic inhibitors", BIOCHEMISTRY, vol. 40, no. 18, 8 May 2001 (2001-05-08), pages 5542 - 5547, XP002261273, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
GB0216097D0 (en) 2002-08-21
WO2004007720A2 (en) 2004-01-22
AU2003254447A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
WO2006015263A3 (en) Lonidamine analogs
AU2003237367A1 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004089415A3 (en) COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
AU2003254038A1 (en) Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer
AU2003282679A1 (en) Hydroxypyrazoles for use against metabolic-related disorders
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
AU2003300791A1 (en) Combination therapy for the treatment of pain
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
AU2003224002A1 (en) Drugs for the arthritis treatment
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
AU2003259246A1 (en) Methods for the use of neurotoxin in the treatment of urologic disorders
UA88655C2 (en) S-mirtazapine for the treatment of hot flush
WO2004007720A3 (en) Treatment of proliferative disorders
AU2002304883A1 (en) Device for the treatment of tumours
WO2005053661A3 (en) Pharmaceutical combinations
AU2003237460A1 (en) Combination treatments for purinoceptor-related disorders
AU2003301758A1 (en) Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2003279180A1 (en) Potentiating the antipyretic action of nonopioid analgesic
AU2003280341A1 (en) Synergistic combinations of dietary fiber and n-saids for the treatment of cancer
AU2003247094A1 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP